Vernalis Group
Vernalis Group was a British-based pharmaceuticals business headquartered in Winnersh. The Vernalis name comes from the verb “to vernalise”, meaning nurture or develop, and is derived from the Latin word vernus, meaning "of the spring". In 1994, Vanguard Medica entered into a deal with SmithKline Beecham to develop SB 209509, its oral selective 5HT1D receptor agonist for the treatment of migraine, later known as VML251 and frovatriptan.
predecessor
Wikipage disambiguates
Link from a Wikipage to another Wikipage
predecessor
primaryTopic
Vernalis Group
Vernalis Group was a British-based pharmaceuticals business headquartered in Winnersh. The Vernalis name comes from the verb “to vernalise”, meaning nurture or develop, and is derived from the Latin word vernus, meaning "of the spring". In 1994, Vanguard Medica entered into a deal with SmithKline Beecham to develop SB 209509, its oral selective 5HT1D receptor agonist for the treatment of migraine, later known as VML251 and frovatriptan.
has abstract
Vernalis Group was a British-b ...... ts acquisition of RiboTargets.
@en
fate
Acquired
@en
founding year
industry
key person
location
successor
type
Wikipage page ID
59,327,686
page length (characters) of wiki page
Wikipage revision ID
923,945,506
Link from a Wikipage to another Wikipage
defunct
fate
Acquired
@en
foundation
industry
key people
CEO Robert G. Mansfield
@en
Location
logo
@en
name
Vernalis Group
@en
predecessor
Vanguard Medica, Cerebrus
@en
successor
type
wikiPageUsesTemplate
subject
comment
Vernalis Group was a British-b ...... wn as VML251 and frovatriptan.
@en
label
Vernalis Group
@en
sameAs
wasDerivedFrom
isPrimaryTopicOf
name
Vernalis Group
@en